Adopting the Evolving Management of HR+/HER2-mBC into Practice

To participate in this activity, please:

Log in Sign Up

Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this 45-minute activity, medical oncologists Sara Hurvitz, MD, and Hope Rugo, MD, discuss key concepts in integrating these evidence-based advancements into clinical practice. They share their thoughts about selecting personalized treatment based on biomarkers, utilizing liquid biopsy techniques to guide therapy for ET resistance, and applying the latest evidence to overcome ET resistance and optimize patient outcomes.

This content is also availble as a podcast: You may listen here.

Course Credit:

1.00 AMA PRA Category 1 CreditTM

Dates:

Opens: 2025-04-10
Closes: 2026-04-10

Target Audience:

This activity is intended for community-and institution-based medical oncologists, pathologists, and other oncology healthcare providers such as nurse practitioners, physician associates, nurses, and pharmacists.

This activity is supported by an independent educational grant from Lilly.

Accreditation Information

Accreditation

In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Alexa Basilio, PharmD, BCOP (Medical Writer)

Employee: McKesson


Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Sara A. Hurvitz, MD

    Professor of Medicine
    Smith Family Endowed Chair in Women’s Health
    Head, Division of Hematology and Oncology | Senior Vice President, Clinical Research Division
    Department of Medicine, UW Medicine | Fred Hutchinson Cancer Center
    Seattle, Washington

  • Hope S. Rugo, MD

    Professor of Medicine
    Winterhof Family Distinguished Professor of Breast Oncology
    University of California San Francisco Comprehensive Cancer Center
    San Francisco, California

Learning Objectives

  • Improve knowledge of how biomarkers guide treatment decisions for patients with HR+/HER2- mBC, focusing on early detection and treatment planning
  • Develop practical skills to effectively utilize liquid biopsy techniques to guide therapy for ET resistance in routine clinical practice
  • Select appropriate ET treatment regimens for patients with HR+/HER2- mBC based on current guidelines, focusing on strategies to overcome ET resistance and optimize ET outcomes

Faculty Disclosures

Sara A. Hurvitz, MD

Advisory Board: BriaCell, Gilead

Consultant: BeiGene, BridgeBio, Luminate

Data Safety Monitoring Board: Atossa, InClin, Inc.                   

Research Support: Arvinas, AstraZeneca, Dantari, Daiichi Sankyo, Lilly, G1-Therapeutics, Genentech, Gilead, Greenwich LifeScience, Immunomedics, Jazz, Menarini, Novartis, Orum, Roche, Orinove, Pfizer, PUMA, Radius, Sanofi, Seattle Genetics, Seagen, Stemline Therapeutics, Zymeworks

Steering Committee: Boehringer Ingelheim, BriaCell, Orum


Hope S. Rugo, MD

Consultant: Chugai, Mylan, Napo, Puma, Sanofi

Research Support: Ambryx, AstraZeneca, Daiichi Sankyo, Genentech, Gilead Sciences, Lilly, Merck, Novartis, OBI Pharma, Pfizer, Roche, Stemline Therapeutics